Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
The use of disposables requires careful consideration and planning.
EMA confirms its recommendation to suspend medicines approved based on GVK Biosciences studies.
FDA issues a Form 483 following inspection of Impax Laboratories' Hayward, CA facility.
The draft guidance document clarifies chemistry, manufacturing, and controls information for marketing applications.
The ICH Steering Committee will meet from June 6–11, 2015 to discuss a variety of harmonization topics.
New guidance complements ICH guidelines on impurities.
Ingredients Insider Cynthia ChallenerConsidering Continuous Crystallization